Unknown

Dataset Information

0

STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas.


ABSTRACT: The motile characteristics and mechanisms that drive the dissemination of diffuse large B-cell lymphoma (DLBCL) are elusive. Here, we show that DLBCL initiates dissemination through activating STAT3-mediated amoeboid migration. Mechanistically, STAT3 activates RHOH transcription, which competes with the RhoGDP dissociation inhibitor RhoGDI? to activate RhoA. In addition, activated STAT3 regulates microtubule dynamics and releases ARHGEF2 to activate RhoA. Both the JAK inhibitor ruxolitinib and the microtubule stabilizer Taxol suppress DLBCL cell dissemination in vivo. A clinical DLBCL sample analysis shows that STAT3-driven amoeboid movement is particularly important for the transition from stage I to stage II. This study elucidates the mechanism of DLBCL dissemination and progression and highlights the potential of combating advanced DLBCL with a JAK/STAT inhibitor or microtubule stabilizer to reduce DLBCL motility; these findings may have a great impact on the development of patient-tailored treatments for DLBCL.

SUBMITTER: Pan YR 

PROVIDER: S-EPMC6135800 | biostudies-literature | 2018 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

STAT3-coordinated migration facilitates the dissemination of diffuse large B-cell lymphomas.

Pan Yi-Ru YR   Chen Chih-Cheng CC   Chan Yu-Tien YT   Wang Hsiao-Jung HJ   Chien Fan-Tso FT   Chen Yeng-Long YL   Liu Jing-Lan JL   Yang Muh-Hwa MH  

Nature communications 20180912 1


The motile characteristics and mechanisms that drive the dissemination of diffuse large B-cell lymphoma (DLBCL) are elusive. Here, we show that DLBCL initiates dissemination through activating STAT3-mediated amoeboid migration. Mechanistically, STAT3 activates RHOH transcription, which competes with the RhoGDP dissociation inhibitor RhoGDIγ to activate RhoA. In addition, activated STAT3 regulates microtubule dynamics and releases ARHGEF2 to activate RhoA. Both the JAK inhibitor ruxolitinib and t  ...[more]

Similar Datasets

| S-EPMC3390034 | biostudies-literature
2006-12-08 | GSE3892 | GEO
| S-EPMC4411286 | biostudies-literature
| S-EPMC4542576 | biostudies-literature
| S-EPMC2214773 | biostudies-literature
2017-05-15 | E-MTAB-4495 | biostudies-arrayexpress
2017-05-15 | E-MTAB-4497 | biostudies-arrayexpress
| S-EPMC3325231 | biostudies-literature
| S-EPMC2748725 | biostudies-literature
| S-EPMC3817189 | biostudies-literature